

Ascendis Pharma A/S  
Tuborg Boulevard 5  
DK-2900 Hellerup, Denmark

November 29, 2017

**VIA EDGAR TRANSMISSION**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, DC 20549

Attention: Frank Wyman  
Lisa Vanjoske

Re: Ascendis Pharma A/S  
Form 20-F for the Year Ended December 31, 2016  
Filed March 22, 2017  
File No. 001-36815

Ladies and Gentlemen:

This letter is to confirm the receipt of your letter dated November 21, 2017 (the "SEC Comment Letter") regarding the Annual Report on Form 20-F for the year ended December 31, 2016 of Ascendis Pharma A/S (the "Company"). The Company plans to provide you with a response to the SEC Comment Letter on or before December 20, 2017.

If you have any questions regarding the foregoing, please call Mark V. Roeder of Latham & Watkins LLP at (650) 463-3043 or the undersigned at (650) 422-3594.

Very truly yours,

/s/ Scott T. Smith

Scott T. Smith

Senior Vice President, Chief Financial Officer

cc: Michael Wolff Jensen  
Mark V. Roeder